The SIMPATHIC Basket Trial: Targeting Shared Pathomechanisms for Personalized Medicine in Rare Diseases

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d7207918e143">This project has received funding from the Horizon Europe research and innovation programme under grant agreement No 101080249. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e145"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e146">Introduction: Drug repurposing is a key strategy in the development of therapies for patients with rare diseases and high unmet medical needs. The International Consortium SIMPATHIC aims to accelerate drug repurposing for rare neurological, neurometabolic, and neuromuscular disorders (neuro-RD’s) by ‘exploiting SIMilarities in clinical and molecular PAThology’. Moving away from the one-drug-one-disease paradigm, we aim to repurpose existing drugs in neuro-RD’s by targeting shared pathomechanisms and clinical manifestations. In a basket trial, treatment effectiveness can be tested in multiple diseases simultaneously and consequently larger patient populations. Based on high-throughput compound screening and disease model systems, sildenafil citrate was identified as a candidate to be tested clinically in multiple neuro-RD's. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e148"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e149">Method: To ensure a solid trial framework, we collaborate with clinicians, translational researchers, regulatory agencies, and patients(representatives). The efficacy and safety of sildenafil citrate will be investigated in a multi-center, randomized, placebo-controlled, crossover basket trial. A master protocol was designed for the basket trial. After sufficient (pre)clinical evidence was provided and reviewed by disease experts, eligible disorders were selected to be included as substudies. Outcome measure hierarchy was determined through consensus by disease experts, researchers, and patient representatives. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e151"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e152">Discussion: A basket trial design proposes an efficient route for evidence-based drug repurposing in rare diseases, which accelerates the route to market authorization and patient access. Moreover, the innovative trial design allows generation of high level of evidence on treatment efficacy in small patient populations, which often miss out on treatments due to limited trial opportunities.

Authors

Institutions

Publication Details

Published
2025-04-12
DOI
https://doi.org/10.14293/idr.25.013tb
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The SIMPATHIC Basket Trial: Targeting Shared Pathomechanisms for Personalized Medicine in Rare Diseases

Bart P.C. van de Warrenburg, Elena Garcia Lara, Mirian C. H. Janssen, Clara D.M. van Karnebeek et al.
Genomics and Rare Diseases
article

The SIMPATHIC Basket Trial: Targeting Shared Pathomechanisms for Personalized Medicine in Rare Diseases

Bart P.C. van de Warrenburg, Elena Garcia Lara, Mirian C. H. Janssen, Clara D.M. van Karnebeek, Ulrich Müller, Tessa Braam, Ir. J. IntHout
article en

Abstract

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d7207918e143">This project has received funding from the Horizon Europe research and innovation programme under grant agreement No 101080249. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e145"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e146">Introduction: Drug repurposing is a key strategy in the development of therapies for patients with rare diseases and high unmet medical needs. The International Consortium SIMPATHIC aims to accelerate drug repurposing for rare neurological, neurometabolic, and neuromuscular disorders (neuro-RD’s) by ‘exploiting SIMilarities in clinical and molecular PAThology’. Moving away from the one-drug-one-disease paradigm, we aim to repurpose existing drugs in neuro-RD’s by targeting shared pathomechanisms and clinical manifestations. In a basket trial, treatment effectiveness can be tested in multiple diseases simultaneously and consequently larger patient populations. Based on high-throughput compound screening and disease model systems, sildenafil citrate was identified as a candidate to be tested clinically in multiple neuro-RD's. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e148"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e149">Method: To ensure a solid trial framework, we collaborate with clinicians, translational researchers, regulatory agencies, and patients(representatives). The efficacy and safety of sildenafil citrate will be investigated in a multi-center, randomized, placebo-controlled, crossover basket trial. A master protocol was designed for the basket trial. After sufficient (pre)clinical evidence was provided and reviewed by disease experts, eligible disorders were selected to be included as substudies. Outcome measure hierarchy was determined through consensus by disease experts, researchers, and patient representatives. <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e151"/><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d7207918e152">Discussion: A basket trial design proposes an efficient route for evidence-based drug repurposing in rare diseases, which accelerates the route to market authorization and patient access. Moreover, the innovative trial design allows generation of high level of evidence on treatment efficacy in small patient populations, which often miss out on treatments due to limited trial opportunities.

Emma Kinderziekenhuis (NL), Amsterdam University Medical Centers (NL)
Openalex Percentile: Top 91%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.